Compugen (CGEN) Q2 2026 Earnings Call Transcript

Compugen (CGEN) reported Q2 2026 revenue of $2.6M (vs. $1.3M in Q2 2025) and net loss of ~$7M (~$0.07/share), with non-GAAP EPS improving to ($0.07) from ($0.08). The company said cash and equivalents were $125.3M as of June 30, 2026, extending its cash runway to fund operations into 2029, while R&D rose to $6.3M primarily due to MAIA-ovarian trial costs. For the MAIA-ovarian COM701 program, Compugen adjusted the control-arm PFS benchmark to ~4 months (from 5.5 months) based on external data but reiterated that interim analysis remains targeted for Q1 2027.

Analysis

The market mechanism here is financing optionality, not near-term revenue. CGEN’s balance sheet pushes the next dilution window well beyond the first interim readout, which should keep the stock from trading like a distressed microcap; that said, the actual value driver is still a single noisy PFS event in a 60-patient, biologically enriched study, so the tape can rerate sharply on any hint of signal. The lowered control-arm assumption helps optics, but it also telegraphs that the standard-of-care baseline is deteriorating, which makes the hurdle easier to clear but the absolute commercial bar less compelling.

The bigger second-order effect is on competitor baskets in ovarian and broader IO. If COM701 shows even a modest PFS separation, it pressures PARP-adjacent maintenance narratives and raises the value of differentiated checkpoint biology versus crowded PD-1/TIGIT programs; if it fails, the whole anti-PVRIG thesis likely gets discounted as a niche asset rather than a platform. The exclusion of liver metastases and the earlier-line design mean any positive signal may not generalize cleanly, so the upside to peak sales could be overestimated by bulls already anchoring on a clean interim.

For AZN, rilvegostomig looks like a portfolio asset with multiple shots on goal, but not a near-term P&L driver. The right way to think about it is option value on a backbone immuno-oncology franchise: each added Phase III increases strategic credibility, yet the market likely needs randomized late-stage data after 2027 before assigning meaningful earnings power. GS-0321 remains even more embryonic; continued dose escalation is supportive, but there is no reason to capitalize milestone headlines into valuation yet.

Contrarian view: the consensus may be overreacting to the revised placebo benchmark as if it meaningfully improves probability of success. It does not change the core problem that a small, exploratory trial must show a clinically obvious effect without biomarker enrichment or validated registrational path. The more likely mispricing is in timing risk: traders may front-run the Q1 2027 readout, but the real move should occur only if management can convert that data into an FDA-credible development plan.

Key Decisions for Investors

• No high-conviction immediate trade in CGEN; keep on watch for pullbacks into the Q1 2027 interim window, because the current setup is still event-dominant and too small for a fundamental re-rate without data.
• If you want exposure, express it as a small, defined-risk long-dated call spread in CGEN only after a catalyst-driven selloff; upside is binary into Q1 2027, but the thesis should be sized as a lottery ticket, not core equity.
• Use AZN as a quieter way to own rilvegostomig optionality, but only as a low-beta hold; do not pay up for the partnership headline until there is randomized Phase III visibility after 2027.
• Avoid shorting CGEN solely on the lower control-arm assumption; the better falsifier is a clean interim PFS miss versus placebo, not the revised benchmark itself.
• Set an alert for any FDA interaction or interim biomarker package from MAIA-ovarian; that would be the first signal that the program is moving from exploratory science to a real registration path.